OGT Initiates Strategic Expansion Plans in North America
News Nov 20, 2012
Oxford Gene Technology (OGT) has announced that it has opened a new office in Tarrytown, New York to support and grow its CytoSure™ cytogenetics arrays and Genefficiency™ next generation sequencing business in the US.
The new office will enable OGT to provide hands-on technical support and training to its existing US customers, and to take advantage of opportunities to develop the business further.
A number of Sales and Support positions including a Field Application Specialist have been created with more new roles expected in the coming months.
OGT has CytoSure and Genefficiency customers in over 30 countries worldwide and serves a potential clinical cytogenetics market of $400million with rapid future growth forecast.
The US is the world’s largest cytogenetics market, and is critical to the development of OGT’s clinical and genomic services business.
Dr Mike Evans, CEO at OGT said, “The opening of the New York office marks a significant milestone for OGT allowing us to offer our US customers even better technical and sales support. Meeting the needs of our customers is our top priority, in a recent survey, 100% of our CytoSure customers said they would recommend OGT to a colleague and we are committed to both continuing and building on this level of expertise and support”.
Dr Madhuri Hegde from Emory University School of Medicine said, “We are delighted that OGT has opened a new US office. The company has a strong reputation and we have always received exceptional service, we look forward to working with the new local support team.”
CytoSure products and Genefficiency services combine advanced microarray and sequencing solutions with class-leading analysis software, enabling clinicians and researchers to accurately detect and interpret chromosomal abnormalities.
The CytoSure range focuses on constitutional genetics, molecular genetics and cancer cytogenetics and is a strong growth area for OGT with an increasing global market share.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018